Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial

Figure 1 Kaplan-Meier analysis of median progression-free survival according to the response evaluation criteria in solid tumors version 1. 1. mPFS: Median progression-free survival; SBRT: Stereotactic body radiotherapy.

Figure 2 Radiographic responses to stereotactic body radiotherapy plus sintilimab. A: Waterfall plots of the proportion of patients with an overall response according to the response evaluation criteria in solid tumors version 1.1; B: The swimmer plot shows the treatment duration for patients receiving stereotactic body radiotherapy and sintilimab. CR: Complete response; PR: Partial response; PD: Progressive disease; EOT: End-of-treatment; SD: Stable disease.

Figure 3 Biomarker analysis. A: Baseline: Progression-free survival (PFS) ≥ 19.7 vs PFS < 19.7; B: 1^st Dose: PFS ≥ 19.7 vs PFS < 19.7; C: 2^nd Dose: PFS ≥ 19.7 vs PFS < 19.7; D: 3^rd Dose: PFS ≥ 19.7 vs PFS < 19.7; E: 4^th Dose: PFS ≥ 19.7 vs PFS < 19.7; F: 5^th Dose: PFS ≥ 19.7 vs PFS < 19.7; G: 6^th Dose: PFS ≥ 19.7 vs PFS < 19.7. PFS: Progression-free survival.